Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: AstraZeneca to Cut 2,300 Sales Jobs as Research to Narrow

If their feet got cold they got cold for good reason. MNKD got their 2nd CRL as we all know. I have accepted the 2nd CRL and moved on from blaming the FDA or shorts. The reality is I as a long going into the last PFUDA was to opptomistic. The reality is switching your delivery device midstream aint exactly a good thing and I have accepted it did require another CRL. Going into the next submittal is a different storey. As long as the trial results are good I see no reason not to be approved unless managment is withholding factual information or the FDA imposes some new out of left field data requirment.

Share
New Message
Please login to post a reply